Aequus Pharmaceuticals (CVE:AQS) said today that it won approval from Health Canada to launch a proof-of-concept trial to evaluate the bioavailability and safety of the company’s long-acting transdermal anti-nausea patch. The device is made up of a combination of pyridoxine and doxylamine. The traditional form is delivered orally up to 4 times per day. The […]
Pharmaceuticals
‘Nanolock’ could help diagnose and treat cancer with individualized therapies
In a study published in ACS Sensors, a team of researchers described how they develop a method to recognize a particular mutation in the genetic code of a cancerous cell. If cancers are caught early enough in the cell mutation process, many of them can be stopped with chemotherapy and other forms of treatment. This new […]
Diasome lands $30m to fund clinical trials of liver-targeted insulin
Diasome Pharmaceuticals said today that it inked a funding deal that could bring the company up to $30 million. The round was led by Medicxi and contributed to by JDRF T1D Fund, Black Beret Life Sciences and McDonald Partners. The Cleveland-based company said it plans to use the funds to support the clinical development of […]
SICPA aims to arm companies against counterfeit drugs, devices
Counterfeit drugs and medical devices are a pervasive problem for the pharmaceutical industry and for consumers. It’s an issue that affects countries around the world, according to SICPA, a firm that has developed secured identification and traceability solutions for companies to assess and manage risks to their products. “In places like Sub-Saharan Africa, 30-40% of […]
Novo Nordisk touts late-stage trial data for Tresiba insulin injection
Novo Nordisk (NYSE:NVO) touted data today from 2 Phase IIIb trials comparing Tresiba insulin degludec to insulin glargine in adults with Type I and Type II diabetes. The results were published in the Journal of the American Medical Association. The Switch trials are the 1st double-blinded insulin trials to compare the hypoglycemia rates and risks in patients […]
GSK inks deal for AI-driven drug discovery
Exscientia inked a drug discovery collaboration with GlaxoSmithKline (NYSE:GSK) that could bring the Scotland-based company up to $37.5 million. As a part of the deal, Exscientia plans to use its artificial-intelligence platform to discover small molecules for up to 10 disease-related targets, as chosen by GSK. GSK is slated to pay Exscientia in preclinical candidate milestone […]
SteadyMed seeks FDA nod for Trevyent drug-device combo
SteadyMed (NSDQ:STDY) said today that it submitted a new drug application to the FDA for its drug-device pulmonary arterial hypertension therapy. The San Ramon, Calif.-based company’s lead product candidate is a combination of treprostinil and the PatchPump prefilled, disposable infusion system. “The submission of our NDA for Trevyent is the latest in a series of significant […]
Sunovion seeks FDA nod for COPD treatment – again
Sunovion Pharmaceuticals said today that the FDA accepted the revised new drug application for its eFlow chronic obstructive pulmonary disease drug-device combo. The submission follows a complete response letter that the FDA issued Sunovion in May. The Marlborough, Mass.-based company didn’t provide details as to why the FDA denied its initial application. The U.S. regulatory watchdog is […]
Windtree Therapeutics reports Phase II data for inhaled surfactant
Windtree Therapeutics (NSDQ:WINT) reported data today from the 221-patient Phase IIb trial of its aerosolized KL4 surfactant for the treatment of respiratory distress syndrome in premature infants. The Aerosurf trial evaluated aerosolized KL4 surfactant administered to premature infants 28 to 32 weeks gestational age in 2 dose groups with up to 2 repeat doses, compared […]
LipoSeuticals closes Series A for novel drug delivery tech
LipoSeuticals said today that it closed a financing round for an undisclosed amount led by Hong Kong-based life sciences fund, Delos Capital. The company has developed a sugar-lipid polymer-based formulation, Sulocence, which boosts drug stability and solubility. LipoSeuticals said it is applying the drug delivery technology to the reformulation of an array of marketed specialty […]